Literature DB >> 30816613

Identification of UGP2 as a progression marker that promotes cell growth and motility in human glioma.

Chun Zeng1, Wenli Xing2, Yanhui Liu1.   

Abstract

Glioblastoma (GBM) is one of the most common highly malignant primary brain tumor with poor prognosis. This study aimed to explore the possible mechanism by bioinformatics method and detect potential function of UGP2 of GBM. Gene expression microarray data of GSE4412 and messenger RNA-sequencing data of GBM with samples clinical information were downloaded from the Gene Expression Omnibus database and The Cancer Genome Atlas database, respectively. Differentially expressed genes (DEGs) analysis using the Kyoto Encyclopedia of Genes and Genomes and Gene Ontology based on R language. A total of 1000 common DEGs were identified in GBM samples, including 353 upregulated and 647 downregulated genes. Based on the random survival forest model, we identified UDP-glucose pyrophosphorylase 2 (UGP2) (upregulated gene) had a significant effect on GBM prognosis. Functional enrichment showed that UGP2 was enriched in the biological progresses of cell proliferation, migration, and invasion. Furthermore, UGP2 expression is aberrantly overexpressed in human glioma and positively correlated with pathologic grade. A loss-of-function study showed that knockdown of UGP2 decreases U251 cell growth, migration, and invasion in vivo and vitro. We proposed the development and progression of human glioma were associated with survival based on bioinformatics analysis. We also found that UGP2 might function as prognostic markers in the pathogenesis of GBM.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  UDP-glucose pyrophosphorylase 2; bioinformatics; biomarker; glioblastoma

Year:  2019        PMID: 30816613     DOI: 10.1002/jcb.28515

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

1.  Targeting cancer's sweet spot: UGP2 as a therapeutic vulnerability.

Authors:  Sunghoon Kim; Andrew Wolfe; Sung Eun Kim
Journal:  Mol Cell Oncol       Date:  2021-10-27

2.  Ethanol promoting the upregulation of C-X-C Motif Chemokine Ligand 1(CXCL1) and C-X-C Motif Chemokine Ligand 6(CXCL6) in models of early alcoholic liver disease.

Authors:  Yao Jiang; Yuge Xi; Yiqin Li; Zhihua Zuo; Chuyi Zeng; Jia Fan; Dan Zhang; Hualin Tao; Yongcan Guo
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  MYCT1 alters the glycogen shunt by regulating selective translation of RACK1-mediated enzymes.

Authors:  Dong-Xue Ding; Yue Wang; Wei Yan; Wei-Neng Fu
Journal:  iScience       Date:  2022-02-22

4.  Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.

Authors:  Ken Hanzawa; Miki Tanaka-Okamoto; Hiroko Murakami; Noriko Suzuki; Mikio Mukai; Hidenori Takahashi; Takeshi Omori; Kenji Ikezawa; Kazuyoshi Ohkawa; Masayuki Ohue; Shunji Natsuka; Yasuhide Miyamoto
Journal:  PLoS One       Date:  2022-04-12       Impact factor: 3.240

5.  N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.

Authors:  Aierpati Maimaiti; Abudireheman Tuersunniyazi; Xianghong Meng; Yinan Pei; Wenyu Ji; Zhaohai Feng; Lei Jiang; Zengliang Wang; Maimaitijiang Kasimu; Yongxin Wang; Xin Shi
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

6.  Mutant Presenilin 1 Dysregulates Exosomal Proteome Cargo Produced by Human-Induced Pluripotent Stem Cell Neurons.

Authors:  Sonia Podvin; Alexander Jones; Qing Liu; Brent Aulston; Charles Mosier; Janneca Ames; Charisse Winston; Christopher B Lietz; Zhenze Jiang; Anthony J O'Donoghue; Tsuneya Ikezu; Robert A Rissman; Shauna H Yuan; Vivian Hook
Journal:  ACS Omega       Date:  2021-05-13

7.  UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.

Authors:  Andrew L Wolfe; Qingwen Zhou; Eneda Toska; Jacqueline Galeas; Angel A Ku; Richard P Koche; Sourav Bandyopadhyay; Maurizio Scaltriti; Carlito B Lebrilla; Frank McCormick; Sung Eun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-03       Impact factor: 12.779

8.  Low UGP2 Expression Is Associated with Tumour Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Qiuyue Hu; Shen Shen; Jianhao Li; Liwen Liu; Xin Liu; Yingying Zhang; Yongjian Zhou; Weiwei Zhu; Yan Yu; Guangying Cui
Journal:  Dis Markers       Date:  2020-07-11       Impact factor: 3.434

9.  Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases.

Authors:  Elena Perenthaler; Anita Nikoncuk; Soheil Yousefi; Woutje M Berdowski; Maysoon Alsagob; Ivan Capo; Herma C van der Linde; Paul van den Berg; Edwin H Jacobs; Darija Putar; Mehrnaz Ghazvini; Eleonora Aronica; Wilfred F J van IJcken; Walter G de Valk; Evita Medici-van den Herik; Marjon van Slegtenhorst; Lauren Brick; Mariya Kozenko; Jennefer N Kohler; Jonathan A Bernstein; Kristin G Monaghan; Amber Begtrup; Rebecca Torene; Amna Al Futaisi; Fathiya Al Murshedi; Renjith Mani; Faisal Al Azri; Erik-Jan Kamsteeg; Majid Mojarrad; Atieh Eslahi; Zaynab Khazaei; Fateme Massinaei Darmiyan; Mohammad Doosti; Ehsan Ghayoor Karimiani; Jana Vandrovcova; Faisal Zafar; Nuzhat Rana; Krishna K Kandaswamy; Jozef Hertecant; Peter Bauer; Mohammed A AlMuhaizea; Mustafa A Salih; Mazhor Aldosary; Rawan Almass; Laila Al-Quait; Wafa Qubbaj; Serdar Coskun; Khaled O Alahmadi; Muddathir H A Hamad; Salem Alwadaee; Khalid Awartani; Anas M Dababo; Futwan Almohanna; Dilek Colak; Mohammadreza Dehghani; Mohammad Yahya Vahidi Mehrjardi; Murat Gunel; A Gulhan Ercan-Sencicek; Gouri Rao Passi; Huma Arshad Cheema; Stephanie Efthymiou; Henry Houlden; Aida M Bertoli-Avella; Alice S Brooks; Kyle Retterer; Reza Maroofian; Namik Kaya; Tjakko J van Ham; Tahsin Stefan Barakat
Journal:  Acta Neuropathol       Date:  2019-12-09       Impact factor: 17.088

10.  An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.

Authors:  Mohammad Sultan; Jacob T Nearing; Justin M Brown; Thomas T Huynh; Brianne M Cruickshank; Emily Lamoureaux; Dejan Vidovic; Margaret L Dahn; Wasundara Fernando; Krysta M Coyle; Carman A Giacomantonio; Morgan G I Langille; Paola Marcato
Journal:  Mol Oncol       Date:  2021-05-18       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.